Clinical Trials Browser

Has results × Leukemia × Brentuximab Vedotin × Clear all

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03264131 2025-02-10

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Phase 2 Active not recruiting

16 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute